Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY23 results · Apr–Jun 2022
Bliss GVS Pharma reported revenue from operations of ₹188.66 crore (up 12.2% from Q1 FY22) and net profit of ₹27.48 crore (up 5.2% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 188.66 | 168.15 | +12.2% | 167.06 | +12.9% |
| Other income | 7.01 | 7.82 | −10.3% | 12.19 | −42.5% |
| Total income | 195.67 | 175.96 | +11.2% | 179.25 | +9.2% |
| Profit before tax | 39.20 | 36.69 | +6.8% | 26.45 | +48.2% |
| Net profit for the period | 27.48 | 26.13 | +5.2% | 23.47 | +17.1% |
| Attributable to shareholders of the company | 25.72 | 24.25 | +6.0% | 19.63 | +31.0% |
| EPS, basic (₹) | 2.48 | 2.35 | +5.5% | 1.90 | +30.5% |
| Net margin (%) | 14.6 | 15.5 | 14.0 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.28 | 133.03 | +10.7% | 138.30 | +6.5% |
| Other income | 18.63 | 7.90 | +136.0% | 12.44 | +49.8% |
| Total income | 165.91 | 140.93 | +17.7% | 150.74 | +10.1% |
| Profit before tax | 32.07 | 29.04 | +10.4% | 16.54 | +93.9% |
| Net profit for the period | 24.65 | 21.66 | +13.8% | 9.47 | +160.2% |
| EPS, basic (₹) | 2.38 | 2.10 | +13.1% | 1.85 | +28.4% |
| Net margin (%) | 16.7 | 16.3 | 6.8 |
Consolidated
- Filed with BSE
- 16 Aug 2022, 11:40 IST
- Board meeting
- 03 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Aug 2022, 11:40 IST
- Board meeting
- 03 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE